www.neurologiepropraxi.cz / Neurol. praxi. 2023;24(6):469-473 / NEUROLOGIE PRO PRAXI 473 SDĚLENÍ Z PRAXE Časná vysoce účinná léčba roztroušené sklerózy: terapeutický úspěch navzdory bezpečnostním překážkám LITERATURA 1. Boz C, Ozakbas S, Terzi M, et al. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing‑remitting multiple sclerosis. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2023;44(6):2121-2129. https://doi.org/10.1007/S10072-023-06608-Z. 2. Brown JWL, Coles A, Horakova D, et al. Association of Initial Disease‑Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA. 2019;321(2):175-187. https://doi.org/10.1001/JAMA.2018.20588. 3. Debouverie M, Pittion‑Vouyovitch S, Louis S, et al. Natural history of multiple sclerosis in a population‑based cohort. European Journal of Neurology. 2008;15(9):916-921. https:// doi.org/10.1111/J.1468-1331.2008.02241.X. 4. Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS – Full Text View – ClinicalTrials.gov. (n.d.). Retrieved April 24, 2022, from https://clinicaltrials.gov/ct2/show/NCT03535298. 5. Dong‑Si T, Richman S, Wattjes MP, et al. Outcome and survival of asymptomatic PML in natalizumab‑treated MS patients. Annals of Clinical and Translational Neurology. 2014;1(10):755764. https://doi.org/10.1002/ACN3.114. 6. Fuentes‑Rumí L, Hernández‑Clares R, Carreón‑Guarnizo E, et al. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high‑dose methylprednisolone schedules. Multiple Sclerosis and Related Disorders. 2020;44:102311. https://doi.org/10.1016/J.MSARD.2020.102311. 7. Goncuoglu C, Tuncer A, Bayraktar‑Ekincioglu A, et al. Factors associated with fingolimod rebound: A single center real‑life experience. Multiple Sclerosis and Related Disorders. 2021;56:103278. https://doi.org/10.1016/J.MSARD.2021.103278. 8. Harding K, Williams O, Willis M, et al. Clinical Outcomes of Escalation vs Early Intensive Disease‑Modifying Therapy in Patients With Multiple Sclerosis. JAMA Neurology. 2019;76(5):536541. https://doi.org/10.1001/JAMANEUROL.2018.4905. 9. He A, Merkel B, Brown JWL, et al. Timing of high‑efficacy therapy for multiple sclerosis: a retrospective observational cohort study. The Lancet. Neurology. 2020;19(4):307-316. https://doi.org/10.1016/S1474-4422(20)30067-3. 10. Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab ‑associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. The Lancet. Neurology. 2017;16(11):925-933. https://doi.org/10.1016/S1474-4422(17)- 30282-X. 11. Hrnciarova T, Drahota J, Spelman T, et al. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing‑remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries. Multiple Sclerosis and Related Disorders. 2023;76. https://doi.org/10.1016/J. MSARD.2023.104803. 12. Kim T, Brinker A, Croteau D, et al. Immune‑mediated colitis associated with ocrelizumab: a new safety risk. Multiple Sclerosis (Houndmills, Basingstoke, England). 2023;29(10):1275-1281. https://doi. org/10.1177/13524585231195854. 13. Nielsen NM, Westergaard T, Rostgaard K, et al. Familial risk of multiple sclerosis: a nationwide cohort study. American Journal of Epidemiology. 2005;162(8):774-8. https://doi: 10.1093/aje/kwi280. 14. Vaněčková M, Horáková D. Role magnetické rezonance při detekci oportunních infekcí v souvislosti s léčbou roztroušené sklerózy. Neurol. praxi. 2016;17(6):377-383. https://doi.org/10.36290/NEU.2016.080. 15. Prosperini L, Mancinelli CR, Solaro CM, et al. Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics. 2020;17(3):994-1004. https://doi.org/10.1007/S13311-020-00847-0. 16. Ryerson LZ, Foley J, Chang I, et al. Risk of natalizumab ‑associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93(15):e1452-e1462. https://doi.org/10.1212/WNL.0000000000008243. 17. Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Multiple Sclerosis (Houndmills, Basingstoke, England). 2012;18(2):143-152. https://doi.org/10.1177/1352458511435105. 18. Spelman T, Magyari M, Piehl F, et al. Treatment Escalation vs. Immediate Initiation of Highly Effective Treatment for Patients With Relapsing‑Remitting Multiple Sclerosis: Data From 2 Different National Strategies. JAMA Neurology. 2021;78(10):1197-1204. https://doi.org/10.1001/JAMANEUROL.2021.2738. 19. Stastna D, Drahota J, Lauer M, et al. The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease‑modifying therapies were initiated from 2013 to 2021. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2023. https://doi.org/10.5507/BP.2023.015. 20. Šťastná D, Menkyová I, Horáková D. Okrelizumab již od první ataky roztroušené sklerózy – milník v úhradových kritériích. Neurol. praxi. 2022;23(4):312-316. https://doi. org/10.36290/NEU.2022.030. 21. Šťastná D, Seňavová J, Andělová M, et al. Internal comorbidities and complications of multiple sclerosis therapy – don’t be caught off guard! Vnitrni Lekarstvi. 2023;69(5):294298. https://doi.org/10.36290/VNL.2023.058. 22. Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial – Full Text View – ClinicalTrials.gov. (n.d.). Retrieved April 24, 2022. Available from https://clinicaltrials. gov/ct2/show/NCT03500328. 23. Uher T, Krasensky J, Malpas C, et al. Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. Neurology(R) Neuroimmunology & Neuroinflammation. 2021;8(3). https://doi.org/10.1212/NXI.0000000000000979. 24. Vaněčková M, Martinková A, Tupý R, et al. The spectrum of MRI findings of progressive multifocal leukoencephalopathy in patients with multiple sclerosis in the Czech Republic. Ceska a Slovenska Neurologie a Neurochirurgie. 2019;82(4):381-390. https://doi.org/10.14735/AMCSNN2019381. 25. Zhu C, Kalincik T, Horakova D, et al. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation. JAMA Neurology. 2023;80(7):739-748. https://doi.org/10.1001/JAMANEUROL.2023.1542. * Možné je více SPINRAZA™ POMÁHÁ PACIENTŮM DOSÁHNOUT VÍCE v porovnání s kontrolní skupinou a přirozeným průběhem onemocnění.1, 2, ** DATA Z KLINICKÝCH STUDIÍ A REÁLNÉ KLINICKÉ PRAXE LÉKU SPINRAZA™ PROKAZUJÍ, ŽE MOŽNÉ JE VÍCE1, 2 ** Přípravek SPINRAZA™ prokázal v randomizovaných kontrolovaných studiích klinicky a statisticky významné zlepšení motorických funkcí v porovnání s kontrolní skupinou.1 V podpůrných studiích a studiích z reálné klinické praxe se presymptomatičtí dětští i dospělí pacienti významně zlepšili v porovnání s přirozeným průběhem onemocnění. Jednotlivé výsledky se mohou lišit v závislosti na závažnosti onemocnění a délce léčby.1, 2 Biogen (Czech Republic) s.r.o., Na Pankráci 1683/127, Praha 4, 140 00 tel.: +420 255 706 200, www.biogen.com.cz, Biogen-225014, říjen 2023 ZKRÁCENOU INFORMACI O PŘÍPRAVKU NAJDETE NA STRANĚ Obrázky jsou inspirovány podobou skutečných lidí žijících se spinální svalovou atrofií a slouží pouze pro ilustraci. Reference: 1. SPINRAZA™ Summary of Product Characteristics. 2. Coratti G, et al. Orphanet J Rare Dis. 2021;16:430. SMA = spinální svalová atrofie. INZ SPIN MORE (BG-225014) 186x74 [10-23].indd 1 24.11.2023 11:42 448.
RkJQdWJsaXNoZXIy NDA4Mjc=